Association of Plasma Neurofilament Light Chain With Glycaemic Control and Insulin Resistance in Middle-Aged Adults

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Jul 7

PMID 35795150

Authors

Rohith N Thota

Pratishtha Chatterjee

Steve Pedrini

Eugene Hone

Jessica J A Ferguson

Manohar L Garg

Ralph N Martins

Affiliations

Soon will be listed here.

Abstract

Aims: This study aimed to determine the association of plasma neurofilament light (NfL), a marker of neurodegeneration, with diabetes status and glycaemic parameters in people with normal glycaemia (NG), pre-diabetes (PD) and type 2 diabetes (T2D).

Methods: Clinical and descriptive data for the diagnostic groups, NG (n=30), PD (n=48) and T2D (n=29), aged between 40 and 75 years were included in this cross-sectional analysis. Plasma NfL levels were analyzed using the ultra-sensitive single-molecule array (Simoa) platform.

Results: A positive correlation was evident between plasma NfL and fasting glucose (r = 0.2824; p = 0.0032). Plasma NfL levels were not correlated with fasting insulin and insulin resistance. Plasma Nfl levels were significantly different across the diabetes groups (T2D >PD >NG, p=0.0046). analysis indicated significantly higher plasma NfL levels in the T2D [12.4 (5.21) pg/mL] group than in the PD [10.2 (4.13) pg/mL] and NG [8.37 (5.65) pg/mL] groups. The relationship between diabetes status and NfL remained significant after adjusting for age, sex, BMI, HOMA-IR and physical activity (adjusted r = 0.271, p = 0.035).

Conclusions: These results show biomarker evidence of neurodegeneration in adults at risk or with T2D. Larger sample size and longitudinal analysis are required to better understand the application of NfL in people with risk and overt T2D.

Citing Articles

Diabetes and Hypertension at Midlife Predict Increases in Biomarkers of Dementia Among Black Americans.

Simons R, Ong M, Lei M, Beach S, Lu Y, Weaver R J Racial Ethn Health Disparities. 2025; .

PMID: 40021611 DOI: 10.1007/s40615-025-02310-2.

Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.

Nystuen K, McNamee S, Akula M, Holton K, Deangelis M, Haider N Bioengineering (Basel). 2024; 11(1).

PMID: 38247923 PMC: 10813760. DOI: 10.3390/bioengineering11010045.

Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers.

Kwon H, Lee E, Kim H, Park S, Park H, Jeong J Alzheimers Dement (Amst). 2023; 15(4):e12502.

PMID: 38026758 PMC: 10654468. DOI: 10.1002/dad2.12502.

Serum neurofilament light chain and cognition decline in US elderly: A cross-sectional study.

Liu X, Chen J, Meng C, Zhou L, Liu Y Ann Clin Transl Neurol. 2023; 11(1):17-29.

PMID: 37902309 PMC: 10791034. DOI: 10.1002/acn3.51929.

Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with Parkinson's disease.

Sheng Z, Ma L, Liu J, Ou Y, Zhao B, Ma Y Front Aging Neurosci. 2023; 14:1061096.

PMID: 36589544 PMC: 9802677. DOI: 10.3389/fnagi.2022.1061096.

References

Gupta A, Giambrone A, Gialdini G, Finn C, Delgado D, Gutierrez J . Silent Brain Infarction and Risk of Future Stroke: A Systematic Review and Meta-Analysis. Stroke. 2016; 47(3):719-25. PMC: 4766016. DOI: 10.1161/STROKEAHA.115.011889. View

Mattsson N, Cullen N, Andreasson U, Zetterberg H, Blennow K . Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019; 76(7):791-799. PMC: 6583067. DOI: 10.1001/jamaneurol.2019.0765. View

Kellar D, Craft S . Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020; 19(9):758-766. PMC: 9661919. DOI: 10.1016/S1474-4422(20)30231-3. View

Biessels G, Staekenborg S, Brunner E, Brayne C, Scheltens P . Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2005; 5(1):64-74. DOI: 10.1016/S1474-4422(05)70284-2. View

Roman-Pintos L, Villegas-Rivera G, Rodriguez-Carrizalez A, Miranda-Diaz A, Cardona-Munoz E . Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. J Diabetes Res. 2017; 2016:3425617. PMC: 5183791. DOI: 10.1155/2016/3425617. View

Quiroz Y, Zetterberg H, Reiman E, Chen Y, Su Y, Fox-Fuller J . Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurol. 2020; 19(6):513-521. PMC: 7417082. DOI: 10.1016/S1474-4422(20)30137-X. View

Osborn K, Khan O, Kresge H, Bown C, Liu D, Moore E . Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimers Dement (Amst). 2019; 11:700-709. PMC: 6827361. DOI: 10.1016/j.dadm.2019.08.008. View

Craft S, Watson G . Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004; 3(3):169-78. DOI: 10.1016/S1474-4422(04)00681-7. View

van Agtmaal M, Houben A, de Wit V, Henry R, Schaper N, Dagnelie P . Prediabetes Is Associated With Structural Brain Abnormalities: The Maastricht Study. Diabetes Care. 2018; 41(12):2535-2543. DOI: 10.2337/dc18-1132. View

10.

Peila R, Rodriguez B, Launer L . Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002; 51(4):1256-62. DOI: 10.2337/diabetes.51.4.1256. View

11.

Ferguson J, Stojanovski E, MacDonald-Wicks L, Garg M . Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial. Metabolism. 2018; 82:22-35. DOI: 10.1016/j.metabol.2017.12.009. View

12.

Korley F, Goldstick J, Mastali M, Van Eyk J, Barsan W, Meurer W . Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus. Stroke. 2019; 50(7):1669-1675. PMC: 6591022. DOI: 10.1161/STROKEAHA.119.024941. View

13.

Polymeris A, Coslovksy M, Aeschbacher S, Sinnecker T, Benkert P, Kobza R . Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Commun. 2020; 2(2):fcaa166. PMC: 7753055. DOI: 10.1093/braincomms/fcaa166. View

14.

Kirkman M, Jones Briscoe V, Clark N, Florez H, Haas L, Halter J . Diabetes in older adults. Diabetes Care. 2012; 35(12):2650-64. PMC: 3507610. DOI: 10.2337/dc12-1801. View

15.

Hafner J, Zadrazil M, Grisold A, Ricken G, Krenn M, Kitzmantl D . Retinal and Corneal Neurodegeneration and Their Association with Systemic Signs of Peripheral Neuropathy in Type 2 Diabetes. Am J Ophthalmol. 2019; 209:197-205. DOI: 10.1016/j.ajo.2019.09.010. View

16.

Celikbilek A, Tanik N, Sabah S, Borekci E, Akyol L, Ak H . Elevated neurofilament light chain (NFL) mRNA levels in prediabetic peripheral neuropathy. Mol Biol Rep. 2014; 41(6):4017-22. DOI: 10.1007/s11033-014-3270-y. View

17.

Papanas N, Vinik A, Ziegler D . Neuropathy in prediabetes: does the clock start ticking early?. Nat Rev Endocrinol. 2011; 7(11):682-90. DOI: 10.1038/nrendo.2011.113. View

18.

Chatterjee P, Pedrini S, Ashton N, Tegg M, Goozee K, Singh A . Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement. 2021; 18(6):1141-1154. DOI: 10.1002/alz.12447. View

19.

Muriach M, Flores-Bellver M, Romero F, Barcia J . Diabetes and the brain: oxidative stress, inflammation, and autophagy. Oxid Med Cell Longev. 2014; 2014:102158. PMC: 4158559. DOI: 10.1155/2014/102158. View

20.

Verdile G, Fuller S, Martins R . The role of type 2 diabetes in neurodegeneration. Neurobiol Dis. 2015; 84:22-38. DOI: 10.1016/j.nbd.2015.04.008. View